JP2023534959A - Ｍｕｃ１－ｃ／細胞外ドメイン（ｍｕｃ１－ｃ／ｅｃｄ）に対する抗体 - Google Patents

Ｍｕｃ１－ｃ／細胞外ドメイン（ｍｕｃ１－ｃ／ｅｃｄ）に対する抗体 Download PDF

Info

Publication number
JP2023534959A
JP2023534959A JP2023502897A JP2023502897A JP2023534959A JP 2023534959 A JP2023534959 A JP 2023534959A JP 2023502897 A JP2023502897 A JP 2023502897A JP 2023502897 A JP2023502897 A JP 2023502897A JP 2023534959 A JP2023534959 A JP 2023534959A
Authority
JP
Japan
Prior art keywords
antibody
cancer
cells
muc1
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023502897A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022016190A5 (enExample
Inventor
スレンダー カルバンダ
ドナルド ダブリュ． キーフ
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
ジーナス オンコロジー リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド, ジーナス オンコロジー リミテッド ライアビリティ カンパニー filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2023534959A publication Critical patent/JP2023534959A/ja
Publication of JPWO2022016190A5 publication Critical patent/JPWO2022016190A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023502897A 2020-07-16 2021-07-15 Ｍｕｃ１－ｃ／細胞外ドメイン（ｍｕｃ１－ｃ／ｅｃｄ）に対する抗体 Pending JP2023534959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052599P 2020-07-16 2020-07-16
US63/052,599 2020-07-16
PCT/US2021/070881 WO2022016190A1 (en) 2020-07-16 2021-07-15 Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)

Publications (2)

Publication Number Publication Date
JP2023534959A true JP2023534959A (ja) 2023-08-15
JPWO2022016190A5 JPWO2022016190A5 (enExample) 2024-06-07

Family

ID=79554266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023502897A Pending JP2023534959A (ja) 2020-07-16 2021-07-15 Ｍｕｃ１－ｃ／細胞外ドメイン（ｍｕｃ１－ｃ／ｅｃｄ）に対する抗体

Country Status (11)

Country Link
US (1) US20230265208A1 (enExample)
EP (1) EP4182354A4 (enExample)
JP (1) JP2023534959A (enExample)
KR (1) KR20230116767A (enExample)
CN (1) CN117693530A (enExample)
AU (1) AU2021310499A1 (enExample)
BR (1) BR112023000728A2 (enExample)
CA (1) CA3186181A1 (enExample)
IL (1) IL299903A (enExample)
MX (1) MX2023000784A (enExample)
WO (1) WO2022016190A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202436357A (zh) * 2023-03-03 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Ｍｕｃ１抗體及使用方法
TW202436343A (zh) * 2023-03-03 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Muc1與cd16a抗體以及其使用方法
WO2025217515A2 (en) 2024-04-12 2025-10-16 Dana-Farber Cancer Institute, Inc. Identification of muc1-c as a target for the treatment of squamous cell carcinomas

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505625A (ja) * 2014-01-29 2017-02-23 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１−ｃ／細胞外ドメイン（ｍｕｃ１−ｃ／ｅｃｄ）に対する抗体
US20180036441A1 (en) * 2016-08-05 2018-02-08 Dana-Farber Cancer Institute, Inc. Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2601417C (en) * 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
EP3130607B1 (en) * 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1* antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505625A (ja) * 2014-01-29 2017-02-23 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１−ｃ／細胞外ドメイン（ｍｕｃ１−ｃ／ｅｃｄ）に対する抗体
US20180036441A1 (en) * 2016-08-05 2018-02-08 Dana-Farber Cancer Institute, Inc. Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)

Also Published As

Publication number Publication date
CN117693530A (zh) 2024-03-12
MX2023000784A (es) 2023-04-18
EP4182354A4 (en) 2024-12-25
KR20230116767A (ko) 2023-08-04
BR112023000728A2 (pt) 2023-03-21
AU2021310499A1 (en) 2023-03-09
CA3186181A1 (en) 2022-01-20
IL299903A (en) 2023-03-01
EP4182354A1 (en) 2023-05-24
WO2022016190A1 (en) 2022-01-20
US20230265208A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
JP7117410B2 (ja) Ｍｕｃ１－ｃ／細胞外ドメイン（ｍｕｃ１－ｃ／ｅｃｄ）に対する抗体
TWI883044B (zh) 使用her3抗原結合分子的癌症之治療及預防
JP2017505625A5 (enExample)
KR20190140943A (ko) 항-cd33 항체 제제
US20250353915A1 (en) Antibodies to galectin-3 and methods of use thereof
JP2011514314A (ja) 抗体及びその誘導体
JP2025129213A (ja) 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用
CA3208721A1 (en) Binding molecules specific for il-21 and uses thereof
JP2023534959A (ja) Ｍｕｃ１－ｃ／細胞外ドメイン（ｍｕｃ１－ｃ／ｅｃｄ）に対する抗体
TW202210523A (zh) 用於調節骨髓樣細胞發炎表型之抗ｖｓｉｇ４組合物及方法以及其用途
CN114641310A (zh) 治疗癌症和其他疾病的靶向α3β1整合素
US20230063625A1 (en) Human antibodies to rift valley fever virus
US20230065377A1 (en) Human antibodies to alphaviruses
US20230181714A1 (en) Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
US20240026035A1 (en) Human ige monoclonal antibodies to antibodies to alpha-gal (galactose-a-1,3-galactose) and uses therefor
US20250277015A1 (en) Human monoclonal antibodies to eastern equine encephalitis virus and uses therefor
US20250304659A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 1 (SARS-CoV-1)
US12037384B2 (en) Human monoclonal antibodies against yellow fever virus and uses therefor
EA049727B1 (ru) Антитела против muc1-c/внеклеточного домена muc1-c (muc1-c/ecd)
WO2023187407A1 (en) Human monoclonal antibodies binding to sars-cov-2 and methods of use thereof
US20240288426A1 (en) Human antibodies to crimean congo hemorrhagic fever virus
WO2025227054A1 (en) Monoclonal antibodies binding to leptin and uses thereof
WO2026006386A1 (en) Generation of human alpha-gal- and tick-specific ige monoclonal antibodies for diagnostic and therapeutic use
WO2024015760A2 (en) Human monoclonal antibodies to omicron variant of severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
CN119233992A (zh) 抗活化蛋白c的人抗体及其用途

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230816

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251003